These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8711438)

  • 21. Augmentation of skin flap survival by selective intraarterial infusion of prostaglandin E1: experimental and clinical studies.
    Okamoto Y; Nakajima T; Yoneda K
    Ann Plast Surg; 1993 Feb; 30(2):154-8. PubMed ID: 8489180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic effect of lipoprostaglandin E1 on sudden hearing loss.
    Ahn JH; Kim MR; Kim HC
    Am J Otolaryngol; 2005; 26(4):245-8. PubMed ID: 15991090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The transepidermal absorption of prostaglandin E1 as a topical ointment: an experimental study of application over a rat skin flap.
    Nakanishi Y; Nakajima T; Yoshimura Y; Okamoto Y; Yamada T
    Ann Plast Surg; 1998 Jan; 40(1):44-7. PubMed ID: 9464695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase in length of experimental skin flaps that survive with dibutyryl cyclic AMP.
    Kusumoto K; Isshiki N; Suzuki S; Ohtsuka M; Nose K
    Scand J Plast Reconstr Surg Hand Surg; 1995 Jun; 29(2):111-6. PubMed ID: 7569808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beneficial effects of intravenous administration of lipo-prostaglandin E1 on the ischemic gastric tube in pigs.
    Tobari S; Ikeda Y; Takami H
    J Surg Res; 2005 Nov; 129(1):79-84. PubMed ID: 16087193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy of different doses of lipo-prostaglandin E1 in the treatment of painful diabetic peripheral neuropathy.
    Hong L; Zhang J; Shen J
    J Diabetes Complications; 2015; 29(8):1283-6. PubMed ID: 26355026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).
    Otomo S; Mizushima Y; Aihara H; Yokoyama K; Watanabe M; Yanagawa A
    Drugs Exp Clin Res; 1985; 11(9):627-31. PubMed ID: 3880049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in the prostaglandin E1-therapy of the intermittent claudication by means of bolus injections of LIPO-prostaglandin E1 (LIPO-PGE1).
    Scheffler P; Gross J; Markwirth T; Maier J; Schieffer H
    Eur J Clin Pharmacol; 1996; 51(3-4):235-9. PubMed ID: 9010691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accumlation of lipoprostaglandin E1 at the anastomotic region after systemic application.
    Okochi M; Ueda K; Kajikawa A
    Microsurgery; 2011 Jul; 31(5):382-7. PubMed ID: 21618280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long beneficial effects after lipo-prostaglandin E1 administration on the ischemic gastric tube in pigs.
    Ikeda Y; Morita N
    Dis Esophagus; 2008; 21(8):765-9. PubMed ID: 18564164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new system of treating wounds by a continuous topical application of medication.
    Sawada Y; Yotsuyanagi T; Hatayama I; Sone K
    Br J Plast Surg; 1990 Jan; 43(1):83-7. PubMed ID: 2310899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostaglandin E1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy.
    Hoshi K; Mizushima Y; Kiyokawa S; Yanagawa A
    Drugs Exp Clin Res; 1986; 12(8):681-5. PubMed ID: 3757764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Echocardiographic evaluation of the ductal morphology in patients with refractoriness to lipo-prostaglandin E1 therapy.
    Takeda N; Hiraishi S; Misawa H; Agata Y; Horiguchi Y; Fujino N; Hirota H; Kawamura S; Ogawa N
    Pediatr Int; 2000 Apr; 42(2):134-8. PubMed ID: 10804727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of vasonatrin peptide on random pattern skin flap survival.
    Wang SP; Lan ZY; Xia W; Zhao X; Ma GJ; Liu B; Pan BH; Guo SZ
    Ann Plast Surg; 2014 Jan; 72(1):94-9. PubMed ID: 23403542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of intravenous administration of prostaglandin E(1) and lipo-prostaglandin E(1) on cochlear blood flow in guinea pigs.
    Nishimura T; Nario K; Hosoi H
    Eur Arch Otorhinolaryngol; 2002 May; 259(5):253-6. PubMed ID: 12107528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of lipid microspheres containing prostaglandin E1 ointment to peripheral ischemic ulcers.
    Sakakibara Y; Jikuya T; Mitsui T
    Dermatology; 1997; 195(3):253-7. PubMed ID: 9407173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipo-PGE1, prostaglandin E1 incorporated in lipid microspheres, protects injury of the liver caused by warm ischemia reperfusion.
    Egashira T; Kim YI; Takayama F; Kudo Y; Yamanaka Y
    Free Radic Biol Med; 1996; 21(3):353-6. PubMed ID: 8855446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers.
    Toyota T; Hirata Y; Ikeda Y; Matsuoka K; Sakuma A; Mizushima Y
    Prostaglandins; 1993 Nov; 46(5):453-68. PubMed ID: 8278621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical administration of prostaglandin E1 with iontophoresis for skin flap viability.
    Asai S; Fukuta K; Torii S
    Ann Plast Surg; 1997 May; 38(5):514-7. PubMed ID: 9160134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Augmentation of surviving flap area by intraarterial vasodilators administered through implantable pumps.
    Morain WD; Pettit RJ; Rothkopf DM; Coombs DW
    Ann Plast Surg; 1983 Jul; 11(1):46-52. PubMed ID: 6577808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.